0 Commentaires
0 Parts
49 Vue
0 Aperçu
Rechercher
Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis
-
Connectez-vous pour aimer, partager et commenter!
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Commentaires 0 Parts 9 Vue 0 Aperçu
-
Piper Sandler cuts Globe Life (GL) to Neutral as Medicare Supplement claims cloud its 2027 outlookPiper Sandler moved Globe Life Inc. (GL) to Neutral from Overweight and cut its target to $165 from $200, citing medical claims and 2027 guidance after a quarter in which health benefits rose 19%. Piper Sandler downgraded Globe Life Inc. (GL) to Neutral from Overweight on Friday and cut its price target to $165 from $200, according to Investing.com. The firm said the insurer lost much of the...0 Commentaires 0 Parts 23 Vue 0 Aperçu